BackGilead Sciences Overview
Gilead Sciences, Inc.

Gilead Sciences Target Price

Analysts' average 12-month price target for Gilead Sciences is $150.

Get informed when a big investor buys or sells

+ Follow

Share Price

$135.87

Average Target Price

$146.928.1% upside

12 analysts in the last 4 months

High: $168 | Low: $120

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05Truist Financial$15010.4% upsideOpen
2026-08-05RBC Capital$1239.5% downsideOpen
2026-07-29Barclays$1456.7% upsideOpen
2026-07-27Morgan Stanley$16521.4% upsideOpen
2026-07-20Leerink PartnersDaina Graybosch$1276.5% downsideOpen
2026-07-08Morgan Stanley$16622.2% upsideOpen
2026-07-07RBC CapitalBrian Abrahams$12011.7% downsideOpen
2026-07-06HSBCRajesh Kumar$15514.1% upsideOpen
2026-06-01RBC CapitalBrian Abrahams$12210.2% downsideOpen
2026-05-20Maxim GroupMichael Okunewitch$16521.4% upsideOpen
2026-05-10Morgan Stanley$16823.6% upsideOpen
2026-05-08Truist Financial$15715.6% upsideOpen
2026-04-10Morgan Stanley$17528.8% upsideOpen
2026-04-08Truist FinancialGregory Renza$15514.1% upsideOpen
2026-03-10JefferiesAkash Tewari$18032.5% upsideOpen
2026-02-19Mizuho Securities$17025.1% upsideOpen
2026-02-19Barclays$15514.1% upsideOpen
2026-02-18UBS$17528.8% upsideOpen
2026-02-11Oppenheimer$16521.4% upsideOpen
2026-02-11Wells FargoMohit Bansal$16521.4% upsideOpen
2026-02-11ScotiabankLouise Chen$17730.3% upsideOpen
2026-02-11NeedhamJoseph Stringer$17025.1% upsideOpen
2026-02-11Cantor Fitzgerald$15514.1% upsideOpen
2026-02-11BMO CapitalEvan Seigerman$16017.8% upsideOpen
2026-02-11Truist Financial$15211.9% upsideOpen
2026-02-11Robert W. Baird$1456.7% upsideOpen
2026-02-11Truist Financial$16219.2% upsideOpen
2026-02-11Morgan Stanley$17125.9% upsideOpen
2026-02-11BernsteinCourtney Breen$16017.8% upsideOpen
2026-01-27Truist Financial$1456.7% upsideOpen
2026-01-26UBS$15514.1% upsideOpen
2026-01-26BMO CapitalEvan David Seigerman$15010.4% upsideOpen
2026-01-13Morgan Stanley$15010.4% upsideOpen
2026-01-07UBSMichael Yee$1456.7% upsideOpen
2025-12-29BernsteinCourtney Breen$1350.6% downsideOpen
2025-12-15Wolfe ResearchAlexandria Hammond$15010.4% upsideOpen
2025-12-12Morgan Stanley$15111.1% upsideOpen
2025-12-10HSBC$1332.1% downsideOpen
2025-11-25BMO CapitalEvan David Seigerman$1350.6% downsideOpen
2025-11-24Truist FinancialGregory Renza$1403% upsideOpen
2025-11-20Mizuho Securities$1403% upsideOpen
2025-10-31RBC Capital$10522.7% downsideOpen
2025-10-31Morgan StanleyTerence Flynn$1478.2% upsideOpen
2025-10-31Wells Fargo$1456.7% upsideOpen
2025-10-09Cantor FitzgeraldCarter Gould$1350.6% downsideOpen
2025-10-06Wells Fargo$1403% upsideOpen
2025-08-11Deutsche BankJames Shin$1350.6% downsideOpen
2025-08-08Morgan StanleyTerence Flynn$1435.2% upsideOpen
2025-08-08Robert W. BairdBrian Skorney$10820.5% downsideOpen
2025-07-14Leerink PartnersDavid Risinger$11416.1% downsideOpen

Gilead Sciences (GILD) FAQ

The latest target price for GILD is $150. Investors often review this figure alongside Gilead Sciences's historical trend and sector peers before judging valuation or financial health.

Gilead Sciences trades near $135.87 while the consensus target sits at $150 (8.1% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting GILD's target price ($150), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Gilead Sciences's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.